Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
|
|
Celldex Therapeutics, Inc. (CLDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/29/2021 |
GN
| Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria |
| 03/05/2021 |
GN
| Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference |
| 02/22/2021 |
GN
| Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference |
| 01/04/2021 |
GN
| Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel |
| 12/09/2020 |
GN
| Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria |
| 11/09/2020 |
GN
| Celldex Presents Data from Oncology Portfolio at SITC 2020 |
| 10/13/2020 |
GN
| Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria |
| 09/10/2020 |
GN
| Celldex Therapeutics to Present at Upcoming Healthcare Conferences |
| 08/24/2020 |
GN
| Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors |
| 08/03/2020 |
GN
| Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call |
| 06/18/2020 |
GN
| Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares |
| 06/15/2020 |
GN
| Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock |
| 06/06/2020 |
GN
| Celldex's KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile |
| 05/06/2020 |
GN
| Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020 |
| 03/26/2020 |
GN
| Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results |
| 03/03/2020 |
GN
| Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program |
| 11/18/2019 |
GN
| Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 |
| 11/12/2019 |
GN
| Celldex Provides Corporate Update and Reports Third Quarter 2019 Results |
| 11/11/2019 |
GN
| Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs |
| 11/08/2019 |
GN
| CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study |
| 10/02/2019 |
GN
| Celldex Therapeutics Announces Upcoming Data Presentations |
| 09/30/2019 |
GN
| Celldex Therapeutics to Present at the Cantor Global Healthcare Conference |
| 06/24/2019 |
GN
| Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer |
| 06/01/2019 |
GN
| Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma |
| 05/07/2019 |
GN
| Celldex Provides Corporate Update and Reports First Quarter 2019 Results |
| 04/02/2019 |
GN
| Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019 |
| 04/01/2019 |
GN
| Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019 |
| 03/01/2019 |
GN
| Celldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call |
| 02/20/2019 |
GN
| Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results |
| 02/08/2019 |
GN
| Celldex Therapeutics Announces Reverse Stock Split |
| 11/09/2018 |
GN
| Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer's 33rd Annual Meeting |
| 10/09/2018 |
GN
| Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Moving into 2018 |
| 08/02/2018 |
GN
| Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call |
| 06/02/2018 |
GN
| Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting |
|
|
|